Clinical Scorecard: Second RSV vaccine dose shows comparable antibody response at 24 months

At a Glance

Key Highlights

• Revaccination met noninferiority criteria for antibody responses at 29 days post-dose.
• Study included 1,502 participants with a 2-to-1 randomization to vaccine or placebo.
• Most solicited reactions were mild or moderate and similar to primary vaccination.
• No serious adverse events related to the vaccine were reported.
• Neutralizing antibody levels remained above baseline 24 months after primary vaccination.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Adults aged 60 years or older previously vaccinated with mRNA-1345.

Revaccination is well tolerated and produces comparable immune responses.

Clinical Best Practices

• Monitor for common mild to moderate reactions post-vaccination.
• Consider revaccination in eligible populations to maintain antibody levels.

Related Resources & Content

• The Journal of Infectious Diseases